The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Momentum appears to be growing around several legislative and regulatory issues that are important to retail pharmacy, including PBM reform at both the state and federal levels.
NCPA issued gratitude to Sens. Cantwell and Grassley for their efforts to "pull back the curtain on PBMs and push for FTC review of anticompetitive PBM practices."
DSN's editor-in-chief Nigel Maynard takes a look at the pace of congressional legislation on issues that are important to retail pharmacies, such as PBM reform and patient access.
The organization publicly commends the administration’s efforts to standardize plan choice by requiring generic drugs be placed on generic tiers and brand-name drugs on brand-name tiers.
In its 90th year, NACDS remains focused on the ever-evolving goal of leading the future of an industry dedicated to advancing health and wellness for all Americans.
